

ACORN CAPITAL MICRO OPPORTUNITIES FUND




INVESTMENT UPDATE
February 2024

Top 5 Stocks Held

Company	Sector
Clarity Pharmaceuticals	Health Care
Meteoric Resources	Resources
Mma Offshore	Industrials
Red 5	Resources
SRG Global	Industrials
Weight Top 5	18.7%

Sector Exposures




Fund Overview

APIR Code	ACQ4764AU
Benchmark	S&P ASX Emerging Companies Accumulation Index
Distributions	Annual
Management Fee	1.20%
Incentive Fee	20% above benchmark
Highwater mark	Yes
Responsible Entity	Evolution Trustees Ltd
Pricing frequency	Daily
Min. investment	\$20,000

Ratings*

Lonsec "Recommended"



Contact: Kate McDermott
Phone: +61 412 260 095
katemcdermott@acorncapital.com.au

Commentary ¹

February 2024 saw the S&P/ASX Emerging Companies Index (XECAL) reversed the weak January, rising 5.15% for the month. IT primarily led the way with a 19% rally with a number of companies reporting better cost control, the Capital Goods sector was up 13% driven by defence names, and Consumer Discretionary was also up 9% with resilient spending and abating inflation, resulting in earnings beating expectation. The local market also took the lead from the strong AI inspired trends in global markets with NASDAQ adding 6.1% during the month.

We are observing an increased level of M&A activity in emerging companies, which we view as a positive lead indicator for both the inherent value in microcaps and a driver of future capital markets activity including the IPO market (which has largely been dormant since 2021).

The portfolio returned -0.3% in February with strong contributions from the Communications sector (+39%) off the back of a strong result from Superloop (+47%), IT (+4%) and Capital Goods (+3%). Detractors to performance over the month included the Discretionary (-10%) sector, primarily NextEd (-47%) as government policies on student Visas remain opaque, Staples (-7%) and Energy (-7%) with uranium stocks declining.

Performance

	Since incept %p.a	3 year % p.a.	1 year %	FYTD %	6 mth %	3 mth %	1 mth %
Micro Opportunities Fund ²	8.58	-6.36	-2.24	-3.47	-4.96	2.06	-0.27
Benchmark	14.34	1.44	-3.23	-0.53	-0.19	6.12	5.15
Alpha	-5.76	-7.80	+0.99	-2.94	-4.77	-4.06	-5.42

Attribution

Contributors			Detractors		
Company	Sector	Impact %	Company	Sector	Impact %
Superloop	Telco	+1.12	NextEd	Discretionary	-1.25
Clarity Pharma	Health Care	+0.78	Impedimed	Health Care	-0.69
Winsome	Resources	+0.55	Orpheus	Energy	-0.41

1. Commentary for month of February 2024. 2. Net performance is based on redemption price for the period, after all fees and costs. Assumes all distributions are reinvested.

This report is published by Acorn Capital Limited ("Acorn") ABN: 51 082 694 531, AFSL: 227605 and is general information only and is not intended as an offer or solicitation with respect to the purchase or sale of any securities by Acorn or the responsible entity and Issuer. Evolution Trustees Limited ("Evolution") ABN: 29 611 839 519 AFSL: 486217 is the responsible entity and Issuer of the Fund. Acorn is the investment or fund manager of the Acorn Capital Micro Opportunities Fund (the Fund) ARSN: 673 344 833. This report does not take into account the investment objectives, financial situation or needs of any particular person. Investors should obtain personal financial advice based on their own particular needs and circumstances before making any investment decision. Any person considering investing, holding or disposing of units in the Fund should review the Product Disclosure Statement for the Fund dated 15 December 2023, Reference Guide, Target Market Determination and any other material published by Acorn. This information is available at www.acorncapital.com.au. Evolution and Acorn do not guarantee repayment of capital or any particular rate of return from the Fund. Past performance is no guarantee of future performance. Investment returns have been calculated in accordance with normal industry practice utilising movements in unit price and assuming reinvestment of all distributions of income and realised profits. The information is current at the date of publication, and whilst all care has been taken in its preparation, neither Acorn nor Evolution gives any representation or warranty as to the reliability, completeness or accuracy of the information contained in this report. Statements in this report have been obtained from and are based upon sources that Acorn believes to be reliable, however Acorn does not guarantee their accuracy, and any such information may be incomplete or condensed. All opinions and estimates included in this report are subject to change without notice. Not to be reproduced without permission.

*The rating issued 12/2023 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2024 Lonsec. All rights reserved

